News >

Long-Term Data Published for Neratinib in HER2+ Breast Cancer

Jason Harris
Published: Friday, Dec 29, 2017

breast cancer
In a 5-year follow-up to the phase III ExteNET trial of women with HER2-positive stage I-IIIc operable breast cancer, investigators found that extended adjuvant therapy with neratinib (Nerlynx) significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.

Other gastrointestinal-related adverse events included nausea (43%), fatigue (27%), vomiting (26%), and abdominal pain (24%). In the placebo arm, 36% of patients had all-grade diarrhea, with a grade 3/4 incidence of 2.0%.
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18:1688-700.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x